Do analysts recommend AIMDW or YARW?

Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than Ainos. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ainos 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Yarrow Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings and valuation, AIMDW or YARW?

Ainos has higher earnings, but lower revenue than Yarrow Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ainos $18.11K N/A N/A N/A N/A Yarrow Bioscience $570K 44.62 -$26.48M -$19.00 N/A

Do analysts prefer YARW or ALVOW?

Yarrow Bioscience presently has a consensus price target of $58.00, indicating a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Yarrow Bioscience is more favorable than Alvotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yarrow Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Alvotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, YARW or ALVOW?

Alvotech has higher revenue and earnings than Yarrow Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Yarrow Bioscience $570K 44.62 -$26.48M -$19.00 N/A Alvotech $559.42M N/A N/A N/A N/A

Does the media favor YARW or ALVOW?

In the previous week, Yarrow Bioscience had 4 more articles in the media than Alvotech. MarketBeat recorded 5 mentions for Yarrow Bioscience and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.67 beat Yarrow Bioscience's score of 0.21 indicating that Alvotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Yarrow Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alvotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer YARW or ARAV?

Yarrow Bioscience currently has a consensus target price of $58.00, indicating a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Yarrow Bioscience is more favorable than Aravive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yarrow Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer YARW or ACABW?

Yarrow Bioscience presently has a consensus price target of $58.00, indicating a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Yarrow Bioscience is more favorable than Atlantic Coastal Acquisition Corp. II. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Yarrow Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Atlantic Coastal Acquisition Corp. II 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, YARW or ACABW?

Atlantic Coastal Acquisition Corp. II has lower revenue, but higher earnings than Yarrow Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Yarrow Bioscience $570K 44.62 -$26.48M -$19.00 N/A Atlantic Coastal Acquisition Corp. II N/A N/A N/A N/A N/A

Do analysts recommend BFRIW or YARW?

Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Yarrow Bioscience is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Yarrow Bioscience 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger earnings & valuation, BFRIW or YARW?

Biofrontera has higher revenue and earnings than Yarrow Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biofrontera $43.20M N/A N/A N/A N/A Yarrow Bioscience $570K 44.62 -$26.48M -$19.00 N/A

Does the media refer more to BFRIW or YARW?

In the previous week, Yarrow Bioscience had 4 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Yarrow Bioscience and 1 mentions for Biofrontera. Yarrow Bioscience's average media sentiment score of 0.21 beat Biofrontera's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biofrontera 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Yarrow Bioscience 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Yarrow Bioscience (YARW) Competitors

$38.28 +0.33 (+0.86%)

As of 09:30 AM Eastern

Compare

YARW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Yarrow Bioscience stock or one of its competitors? MarketBeat compares Yarrow Bioscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Yarrow Bioscience include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Yarrow Bioscience compare to Ainos?

Ainos (NASDAQ:AIMDW) and Yarrow Bioscience (NASDAQ:YARW) are related companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Ainos has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Ainos' return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ainos	N/A	N/A	N/A
Yarrow Bioscience	-4,726.21%	-70.42%	-63.46%

Ainos has higher earnings, but lower revenue than Yarrow Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ainos	$18.11K	N/A	N/A	N/A	N/A
Yarrow Bioscience	$570K	44.62	-$26.48M	-$19.00	N/A

Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts plainly believe Yarrow Bioscience is more favorable than Ainos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ainos	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Yarrow Bioscience had 5 more articles in the media than Ainos. MarketBeat recorded 5 mentions for Yarrow Bioscience and 0 mentions for Ainos. Yarrow Bioscience's average media sentiment score of 0.21 beat Ainos' score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
Ainos	Neutral
Yarrow Bioscience	Neutral

83.8% of Yarrow Bioscience shares are owned by institutional investors. 3.0% of Yarrow Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Yarrow Bioscience beats Ainos on 8 of the 11 factors compared between the two stocks.

How does Yarrow Bioscience compare to Alvotech?

Yarrow Bioscience (NASDAQ:YARW) and Alvotech (NASDAQ:ALVOW) are related companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Alvotech has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Alvotech's return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-70.42%	-63.46%
Alvotech	N/A	N/A	N/A

Alvotech has higher revenue and earnings than Yarrow Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	44.62	-$26.48M	-$19.00	N/A
Alvotech	$559.42M	N/A	N/A	N/A	N/A

Yarrow Bioscience presently has a consensus price target of $58.00, indicating a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, research analysts plainly believe Yarrow Bioscience is more favorable than Alvotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Alvotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Yarrow Bioscience had 4 more articles in the media than Alvotech. MarketBeat recorded 5 mentions for Yarrow Bioscience and 1 mentions for Alvotech. Alvotech's average media sentiment score of 0.67 beat Yarrow Bioscience's score of 0.21 indicating that Alvotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Yarrow Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alvotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

83.8% of Yarrow Bioscience shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Yarrow Bioscience beats Alvotech on 6 of the 11 factors compared between the two stocks.

How does Yarrow Bioscience compare to Aravive?

Yarrow Bioscience (NASDAQ:YARW) and Aravive (NASDAQ:ARAV) are related companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Aravive has lower revenue, but higher earnings than Yarrow Bioscience. Yarrow Bioscience is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	44.62	-$26.48M	-$19.00	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

In the previous week, Yarrow Bioscience had 5 more articles in the media than Aravive. MarketBeat recorded 5 mentions for Yarrow Bioscience and 0 mentions for Aravive. Yarrow Bioscience's average media sentiment score of 0.21 beat Aravive's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Yarrow Bioscience	Neutral
Aravive	Neutral

83.8% of Yarrow Bioscience shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Yarrow Bioscience currently has a consensus target price of $58.00, indicating a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher possible upside, analysts clearly believe Yarrow Bioscience is more favorable than Aravive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aravive has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Aravive's return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-70.42%	-63.46%
Aravive	N/A	N/A	N/A

Summary

Yarrow Bioscience beats Aravive on 7 of the 12 factors compared between the two stocks.

How does Yarrow Bioscience compare to Atlantic Coastal Acquisition Corp. II?

Yarrow Bioscience (NASDAQ:YARW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are related companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, profitability, institutional ownership and earnings.

Atlantic Coastal Acquisition Corp. II has lower revenue, but higher earnings than Yarrow Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Yarrow Bioscience	$570K	44.62	-$26.48M	-$19.00	N/A
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A	N/A	N/A

Atlantic Coastal Acquisition Corp. II has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Yarrow Bioscience	-4,726.21%	-70.42%	-63.46%
Atlantic Coastal Acquisition Corp. II	N/A	N/A	N/A

83.8% of Yarrow Bioscience shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Yarrow Bioscience presently has a consensus price target of $58.00, indicating a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Yarrow Bioscience is more favorable than Atlantic Coastal Acquisition Corp. II.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Atlantic Coastal Acquisition Corp. II	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Yarrow Bioscience had 5 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 5 mentions for Yarrow Bioscience and 0 mentions for Atlantic Coastal Acquisition Corp. II. Yarrow Bioscience's average media sentiment score of 0.21 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
Yarrow Bioscience	Neutral
Atlantic Coastal Acquisition Corp. II	Neutral

Summary

Yarrow Bioscience beats Atlantic Coastal Acquisition Corp. II on 8 of the 11 factors compared between the two stocks.

How does Yarrow Bioscience compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Yarrow Bioscience (NASDAQ:YARW) are related companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

In the previous week, Yarrow Bioscience had 4 more articles in the media than Biofrontera. MarketBeat recorded 5 mentions for Yarrow Bioscience and 1 mentions for Biofrontera. Yarrow Bioscience's average media sentiment score of 0.21 beat Biofrontera's score of 0.00 indicating that Yarrow Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biofrontera	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Yarrow Bioscience	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Yarrow Bioscience has a consensus price target of $58.00, suggesting a potential upside of 52.79%. Given Yarrow Bioscience's stronger consensus rating and higher probable upside, analysts plainly believe Yarrow Bioscience is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Yarrow Bioscience	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Biofrontera has higher revenue and earnings than Yarrow Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$43.20M	N/A	N/A	N/A	N/A
Yarrow Bioscience	$570K	44.62	-$26.48M	-$19.00	N/A

83.8% of Yarrow Bioscience shares are held by institutional investors. 3.0% of Yarrow Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biofrontera has a net margin of 0.00% compared to Yarrow Bioscience's net margin of -4,726.21%. Biofrontera's return on equity of 0.00% beat Yarrow Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	N/A	N/A	N/A
Yarrow Bioscience	-4,726.21%	-70.42%	-63.46%

Summary

Yarrow Bioscience beats Biofrontera on 7 of the 11 factors compared between the two stocks.

Get Yarrow Bioscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding YARW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

YARW vs. The Competition

Export

Metric	Yarrow Bioscience	Pharmaceutical Preparations Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$22.43M	$13.49M	$10.71B	$12.77B
Dividend Yield	N/A	N/A	120.51%	10.01%
P/E Ratio	N/A	N/A	28.36	25.53
Price / Sales	44.62	45.10	331.78	92.31
Price / Cash	N/A	N/A	24.53	49.39
Price / Book	0.91	0.80	4.59	6.11
Net Income	-$26.48M	-$32.56M	$609.24M	$347.58M
7 Day Performance	24.66%	14.09%	4.27%	4.91%
1 Month Performance	N/A	-41.51%	0.12%	-2.06%
1 Year Performance	N/A	N/A	13.79%	21.03%

Yarrow Bioscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
YARW Yarrow Bioscience	2.4471 of 5 stars	$38.29 +0.9%	$58.00 +51.5%	N/A	$25.65M	$570K	N/A	30	News Coverage Analyst Forecast Gap Up
AIMDW Ainos	N/A	$0.09 +11.8%	N/A	-5.8%	$0.00	$18.11K	N/A	40	Positive News Gap Up
ALVOW Alvotech	N/A	$0.15 flat	N/A	-90.6%	$0.00	$559.42M	N/A	4
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
ACABW Atlantic Coastal Acquisition Corp. II	N/A	$0.00 flat	N/A	N/A	$0.00	N/A	N/A	15

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:YARW) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Yarrow Bioscience (YARW) Competitors

YARW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

How does Yarrow Bioscience compare to Ainos?

Summary

How does Yarrow Bioscience compare to Alvotech?

Summary

How does Yarrow Bioscience compare to Aravive?

Summary

How does Yarrow Bioscience compare to Atlantic Coastal Acquisition Corp. II?

Summary

How does Yarrow Bioscience compare to Biofrontera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Yarrow Bioscience (YARW) Competitors

YARW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

How does Yarrow Bioscience compare to Ainos?

Is AIMDW or YARW more profitable?

Which has stronger earnings and valuation, AIMDW or YARW?

Do analysts recommend AIMDW or YARW?

Does the media prefer AIMDW or YARW?

Do institutionals and insiders have more ownership in AIMDW or YARW?

Summary

How does Yarrow Bioscience compare to Alvotech?

Is YARW or ALVOW more profitable?

Which has stronger earnings & valuation, YARW or ALVOW?

Do analysts prefer YARW or ALVOW?

Does the media favor YARW or ALVOW?

Do institutionals and insiders have more ownership in YARW or ALVOW?

Summary

How does Yarrow Bioscience compare to Aravive?

Which has better valuation & earnings, YARW or ARAV?

Does the media favor YARW or ARAV?

Do insiders and institutionals have more ownership in YARW or ARAV?

Do analysts prefer YARW or ARAV?

Is YARW or ARAV more profitable?

Summary

How does Yarrow Bioscience compare to Atlantic Coastal Acquisition Corp. II?

Which has higher earnings and valuation, YARW or ACABW?

Is YARW or ACABW more profitable?

Do insiders & institutionals have more ownership in YARW or ACABW?

Do analysts prefer YARW or ACABW?

Does the media favor YARW or ACABW?

Summary

How does Yarrow Bioscience compare to Biofrontera?

Does the media refer more to BFRIW or YARW?

Do analysts recommend BFRIW or YARW?

Which has stronger earnings & valuation, BFRIW or YARW?

Do insiders and institutionals believe in BFRIW or YARW?

Is BFRIW or YARW more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

YARW vs. The Competition

Yarrow Bioscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools